Novocure to provide TTF therapy access to US clinical centers

Novocure is set to provide access of its NovoTTF-100A system to four clinical centers in the US.

NovoTTF-100A system is a non-invasive, portable device which is designed to treat recurrent glioblastoma multiforme (GBM).

Tumor Treating Fields (TTF) therapy delivers non-invasive, insulated transducer arrays that are placed directly on the skin in the region of the tumor.

The NovoTTF-100A device creates a low intensity, alternating electric field within the tumor which leads to death of the cancer cells prior to division.

The company said the TTF therapy has been shown in vitro and in vivo to effectively inhibit tumor growth by inducing cell death.